[-2]Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute Early Detection Research Network Validation Study

Journal of Urology

Volumn 180, Issue 2, 2008, Pages 539-543

  Sokoll, Lori J ^a   Wang, Yinghui ^c   Feng, Ziding ^c   Kagan, Jacob ^b   Partin, Alan W ^a   Sanda, Martin G ^d   Thompson, Ian M ^e   Chan, Daniel W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c USA   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e University of Texas Health Science Center   (United States)

Author keywords

biological; early diagnosis; prostate specific antigen; prostatic neoplasms; tumor markers

Indexed keywords

[-2]PROENZYME PROSTATE SPECIFIC ANTIGEN; BENIGN PROSTATE SPECIFIC ANTIGEN; ENZYME PRECURSOR; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SEX HORMONE DETERMINATION; STATISTICAL MODEL; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; EARLY DIAGNOSIS; ENZYME PRECURSORS; HUMANS; MALE; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 46449132555     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.04.015     Document Type: Article

References (20)

1. Mikolajczyk S.D., Marks L.S., Partin A.W., and Rittenhouse H.G. Free prostate-specific antigen in serum is becoming more complex. Urology 59 (2002) 797
2. Mikolajczyk S.D., Millar L.S., Wang T.J., Rittenhouse H.G., Marks L.S., Song W., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60 (2000) 756
3. Mikolajczyk S.D., Catalona W.J., Evans C.L., Linton H.J., Millar L.S., Marker K.M., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50 (2004) 1017
4. Mikolajczyk S.D., Millar L.S., Wang T.J., Rittenhouse H.G., Wolfert R.L., Marks L.S., et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (2000) 41
5. Zhang W.M., Leinonen J., Kalkkinen N., Dowell B., and Stenman U.H. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 41 (1995) 1567
6. Chan T.Y., Mikolajczyk S.D., Lecksell K., Shue M., Rittenhouse H.G., Partin A.W., et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 62 (2003) 177
7. Catalona W.J., Bartsch G., Rittenhouse H.G., Evans C.L., Linton H.J., Amirkhan A., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170 (2003) 2181
8. Khan M.A., Partin A.W., Rittenhouse H.G., Mikolajczyk S.D., Sokoll L.J., Chan D.W., et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 170 (2003) 723
9. Naya Y., Fritsche H.A., Bhadkamkar V.A., Mikolajczyk S.D., Rittenhouse H.G., and Babaian R.J. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol 23 (2005) 16
10. Sokoll L.J., Chan D.W., Mikolajczyk S.D., Rittenhouse H.G., Evans C.L., Linton H.J., et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology 61 (2003) 274
11. Catalona W.J., Bartsch G., Rittenhouse H.G., Evans C.L., Linton H.J., Horninger E., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 (2004) 2239
12. de Vries S.H., Raaijmakers R., Blijenberg B.G., Mikolajczyk S.D., Rittenhouse H.G., and Schroder F.H. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology 65 (2005) 926
13. Weinzierl C.F., Lafranechere S.M., Su S.X., Arockiasamy D.A., Hanson T.P., and Mizrahi I.A. Analytical performance of the Access BPH-A assay from Beckman Coulter. Clin Chem 52 (2006) E48
14. Weinzierl C.F., Su S.X., Pierson T.B., Arockiasamy D.A., Mizrahi I.A., Broyles D.A., et al. Measuring [-2]proPSA in serum: analytical performance of the Access p2PSA assay from Beckman Coulter. Clin Chem 52 (2007) A178
15. Catalona W.J., Smith D.S., Wolfert R.L., Wang T.J., Rittenhouse H.G., Ratliff T.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274 (1995) 1214
16. Partin A.W., Brawer M.K., Bartsch G., Horninger W., Taneja S.S., Lepor H., et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 170 (2003) 1787
17. Bangma C.H., Wildhagen M.F., Yurdakul G., Schroder F.H., and Blijenberg B.G. The value of (-7, -5) pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 93 (2004) 720
18. Lein M., Semjonow A., Graefen M., Kwiatkowski M., Abramjuk C., Stephan C., et al. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 174 (2005) 2150
19. Stephan C., Meyer H.A., Kwiatkowski M., Recker F., Camman H., Loening S.A., et al. A (-5, -7) proPSA based artificial neural network to detect prostate cancer. Eur Urol 50 (2006) 1014
20. Skates S.J., Horick N.K., Moy J.M., Minihan A.M., Seiden M.V., Marks J.R., et al. Pooling of case specimens to create standard serum sets for screening cancer biomarkers. Cancer Epidemiol Biomarkers Prev 16 (2007) 334